Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price19.88 USD
Fair value23.86
Our investment reviews on this name
2026-10-29Read Markdown19.75+0.7% to today Accumulation gives way to Markdown after a 7% slide in 7 days
2026-10-22Read Accumulation21.13-5.9% to today Markdown gives way to Accumulation with volume flow in agreement
2026-10-02Read Markdown20.74-4.1% to today ✓Markup gives way to Markdown
2026-07-02Read Markup20.52-3.1% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Compagnie Financière Richemont SA holds its Markdown at $19.88. Consolidating, no directional conviction, held for 111 days.
As held on the ledger · 2026-10-29
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 111 days
Price at the screen
$19.88
Valuation
29.24 trailing · 20.14 forward price to earnings
Values screen
PASS
Beta
1.08
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.81%
Below 33%
Interest-bearing debt is just 12.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.41%
Below 33%
Cash held in interest-bearing accounts and securities is 14.4% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.99%
Below 5%
Only 1.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Compagnie Financière Richemont clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CFRUY's ethical verdict changes
Today CFRUY passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-29 screen. The gold marker is the market price at the same screen. A 20.0% margin of safety to the base estimate.
Third-party analyst targets: 3 covering, consensus None. The average target sits +31% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Luxury Goods With Ethical Credentials
Compagnie Financière Richemont SA is a luxury goods company that, despite its high-end allure, has a price tag just a touch above its fair value, making it a marginal contender. Picture a sleek, glossy Richemont watch—exquisite, yes, but is it worth the slight premium? The company's revenue growth is a modest 4%, yet it boasts a healthy 16% profit margin and a 15% return on equity, showcasing its luxury market resilience.
Why it stands out is its moderate moat, suggesting a competitive advantage in the luxury goods space. With a forward P/E of 22.9x and a consensus median target price of $23, the market is valuing Richemont with a conservative outlook, which is slightly above its current price.
However, the risk to consider is its cyclical nature, as the luxury goods sector can be sensitive to economic downturns. Although the ethical screen gives Richemont a pass, investors must be mindful of the cyclical value trap, where the current valuation might seem attractive but could be reflective of peak earnings. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CFRUY trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markdown · changed$19.75-6.5%Entry 9
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22.
2026-10-15Markdown$20.55-0.9%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22.
2026-10-02Markdown · changed$20.74-9.2%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.2% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22. Since the last review it its composite score rose.
2026-08-25Markup$22.83-4.8%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22.
2026-07-24Markup$23.99+16.9%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22.
2026-07-18Markup$20.52+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (3 analysts) rates it buy, with a mean price target of $22.
2026-07-03Markup$20.52+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$20.52Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.